Search

Your search keyword '"Gisslinger, B."' showing total 13 results
Start Over Author "Gisslinger, B." Publication Type Electronic Resources
13 results on '"Gisslinger, B."'

1. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

Author

Sant'Antonio, E., Guglielmelli, P., Pieri, L., Primignani, M., Randi, M. L., Santarossa, C., Rumi, E., Cervantes, F., Delaini, F., Carobbio, A., Betti, S., Rossi, Elena, Lavi, N., Harrison, C. N., Curto-Garcia, N., Gisslinger, H., Gisslinger, B., Specchia, G., Ricco, A., Vianelli, N., Polverelli, N., Koren-Michowitz, M., Ruggeri, M., Girodon, F., Ellis, M., Iurlo, A., Mannelli, F., Mannelli, L., Sordi, B., Loscocco, G. G., Cazzola, M., De Stefano, Valerio, Barbui, T., Tefferi, A., Vannucchi, A. M., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Sant'Antonio, E., Guglielmelli, P., Pieri, L., Primignani, M., Randi, M. L., Santarossa, C., Rumi, E., Cervantes, F., Delaini, F., Carobbio, A., Betti, S., Rossi, Elena, Lavi, N., Harrison, C. N., Curto-Garcia, N., Gisslinger, H., Gisslinger, B., Specchia, G., Ricco, A., Vianelli, N., Polverelli, N., Koren-Michowitz, M., Ruggeri, M., Girodon, F., Ellis, M., Iurlo, A., Mannelli, F., Mannelli, L., Sordi, B., Loscocco, G. G., Cazzola, M., De Stefano, Valerio, Barbui, T., Tefferi, A., Vannucchi, A. M., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Myeloproliferative Neoplasms (MPN) course can be complicated by thrombosis involving unusual sites as the splanchnic veins (SVT). Their management is challenging, given their composite vascular risk. We performed a retrospective, cohort study in the framework of the International Working Group for MPN Research and Treatment (IWG-MRT), and AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM). A total of 518 MPN-SVT cases were collected and compared with 1628 unselected, control MPN population, matched for disease subtype. Those with MPN-SVT were younger (median 44 years) and enriched in females compared to controls; PV (37.1%) and ET (34.4%) were the most frequent diagnoses. JAK2V617F mutation was highly prevalent (90.2%), and 38.6% of cases had an additional hypercoagulable disorder. SVT recurrence rate was 1.6 per 100 patient-years. Vitamin K-antagonists (VKA) halved the incidence of recurrence (OR 0.48), unlike cytoreduction (OR 0.96), and were not associated with overall or gastrointestinal bleeding in multivariable analysis. Esophageal varices were the only independent predictor for major bleeding (OR 17.4). Among MPN-SVT, risk of subsequent vascular events was skewed towards venous thromboses compared to controls. However, MPN-SVT clinical course was overall benign: SVT were enriched in PMF with lower IPSS, resulting in significantly longer survival than controls; survival was not affected in PV and slightly reduced in ET. MPN-U with SVT (n = 55) showed a particularly indolent phenotype, with no signs of disease evolution. In the to-date largest, contemporary cohort of MPN-SVT, VKA were confirmed effective in preventing recurrence, unlike cytoreduction, and safe; the major risk factor for bleeding was esophageal varices that therefore represent a major therapeutic target.

Published
2020

2. Germline RBBP6 mutations in familial myeloproliferative neoplasm

Author

Harutyunyan, A.S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., Chen, D., Milosevic Feenstra, J.D., Jager, R., Gisslinger, B., Gisslinger, H., Rumi, E., Passamonti, F., Pietra, D., Muller, A.C., Parapatics, K., Breitwieser, F.P., Herrmann, R., Colinge, J., Bennett, K.L., Superti-Furga, G., Cazzola, M., Hammond, E., Kralovics, R., Harutyunyan, A.S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., Chen, D., Milosevic Feenstra, J.D., Jager, R., Gisslinger, B., Gisslinger, H., Rumi, E., Passamonti, F., Pietra, D., Muller, A.C., Parapatics, K., Breitwieser, F.P., Herrmann, R., Colinge, J., Bennett, K.L., Superti-Furga, G., Cazzola, M., Hammond, E., and Kralovics, R.

Abstract

Letter to the Editor

Published
2016

3. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

Author

Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wolfler, A., Burgstaller, S., Buxhofer-Ausch, V., Schalling, M., Krauth, M-T, Schiefer, A-I, Kornauth, C., Simonitsch-Klupp, I., Beham-Schmid, C., Mullauer, L., Thiele, J., Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wolfler, A., Burgstaller, S., Buxhofer-Ausch, V., Schalling, M., Krauth, M-T, Schiefer, A-I, Kornauth, C., Simonitsch-Klupp, I., Beham-Schmid, C., Mullauer, L., and Thiele, J.

Abstract

Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of Standards in Haematology (BCSH) criteria that are predominantly based on exclusion and not necessarily on bone marrow (BM) morphology, or the World Health Organization (WHO) criteria that require BM examination as essential criterion. We studied the morphological and clinical features in patients diagnosed according either to the BCSH (n = 238) or the WHO guidelines (n = 232). The BCSH-defined ET cohort was reevaluated by applying the WHO classification. At presentation, patients of the BCSH group showed significantly higher values of serum lactate dehydrogenase and had palpable splenomegaly more frequently. Following the WHO criteria, the re-evaluation of the BCSH-diagnosed ET cohort displayed a heterogeneous population with 141 (59.2%) ET, 77 (32.4%) prefibrotic primary myelofibrosis (prePMF), 16 (6.7%) polycythemia vera and 4 (1.7%) primary myelofibrosis. Contrasting WHO-confirmed ET, the BCSH cohort revealed a significant worsening of fibrosis-free survival and prognosis. As demonstrated by the clinical data and different outcomes between WHO-diagnosed ET and prePMF, these adverse features were generated by the inadvertent inclusion of prePMF to the BCSH group. Taken together, the diagnosis of ET without a scrutinized examination of BM biopsy specimens will generate a heterogeneous cohort of patients impairing an appropriate clinical management.

Published
2016

4. A MULTICENTER EVALUATION OF THE REVISED 2015 WHO MINOR CRITERIA FOR PREFIBROTIC PRIMARY MYELOFIBROSIS

Author

Jeryczynski, G., Albert, W., Gisslinger, B., Schalling, M., Burgstaller, S., Buxhofer-Ausch, V., Krauth, M. T., Geissler, K., Schloegl, E., Sliwa, T., Schiefer, A. I., Muellauer, L., Simonitsch-Klupp, I., Beham-Schmid, C., Thiele, J., Gisslinger, H., Jeryczynski, G., Albert, W., Gisslinger, B., Schalling, M., Burgstaller, S., Buxhofer-Ausch, V., Krauth, M. T., Geissler, K., Schloegl, E., Sliwa, T., Schiefer, A. I., Muellauer, L., Simonitsch-Klupp, I., Beham-Schmid, C., Thiele, J., and Gisslinger, H.

Published
2016

5. Germline RBBP6 mutations in familial myeloproliferative neoplasm

Author

Harutyunyan, A.S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., Chen, D., Milosevic Feenstra, J.D., Jager, R., Gisslinger, B., Gisslinger, H., Rumi, E., Passamonti, F., Pietra, D., Muller, A.C., Parapatics, K., Breitwieser, F.P., Herrmann, R., Colinge, J., Bennett, K.L., Superti-Furga, G., Cazzola, M., Hammond, E., Kralovics, R., Harutyunyan, A.S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., Chen, D., Milosevic Feenstra, J.D., Jager, R., Gisslinger, B., Gisslinger, H., Rumi, E., Passamonti, F., Pietra, D., Muller, A.C., Parapatics, K., Breitwieser, F.P., Herrmann, R., Colinge, J., Bennett, K.L., Superti-Furga, G., Cazzola, M., Hammond, E., and Kralovics, R.

Abstract

Letter to the Editor

Published
2016

6. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

Author

Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wolfler, A., Burgstaller, S., Buxhofer-Ausch, V., Schalling, M., Krauth, M-T, Schiefer, A-I, Kornauth, C., Simonitsch-Klupp, I., Beham-Schmid, C., Mullauer, L., Thiele, J., Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wolfler, A., Burgstaller, S., Buxhofer-Ausch, V., Schalling, M., Krauth, M-T, Schiefer, A-I, Kornauth, C., Simonitsch-Klupp, I., Beham-Schmid, C., Mullauer, L., and Thiele, J.

Abstract

Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of Standards in Haematology (BCSH) criteria that are predominantly based on exclusion and not necessarily on bone marrow (BM) morphology, or the World Health Organization (WHO) criteria that require BM examination as essential criterion. We studied the morphological and clinical features in patients diagnosed according either to the BCSH (n = 238) or the WHO guidelines (n = 232). The BCSH-defined ET cohort was reevaluated by applying the WHO classification. At presentation, patients of the BCSH group showed significantly higher values of serum lactate dehydrogenase and had palpable splenomegaly more frequently. Following the WHO criteria, the re-evaluation of the BCSH-diagnosed ET cohort displayed a heterogeneous population with 141 (59.2%) ET, 77 (32.4%) prefibrotic primary myelofibrosis (prePMF), 16 (6.7%) polycythemia vera and 4 (1.7%) primary myelofibrosis. Contrasting WHO-confirmed ET, the BCSH cohort revealed a significant worsening of fibrosis-free survival and prognosis. As demonstrated by the clinical data and different outcomes between WHO-diagnosed ET and prePMF, these adverse features were generated by the inadvertent inclusion of prePMF to the BCSH group. Taken together, the diagnosis of ET without a scrutinized examination of BM biopsy specimens will generate a heterogeneous cohort of patients impairing an appropriate clinical management.

Published
2016

7. A MULTICENTER EVALUATION OF THE REVISED 2015 WHO MINOR CRITERIA FOR PREFIBROTIC PRIMARY MYELOFIBROSIS

Author

Jeryczynski, G., Albert, W., Gisslinger, B., Schalling, M., Burgstaller, S., Buxhofer-Ausch, V., Krauth, M. T., Geissler, K., Schloegl, E., Sliwa, T., Schiefer, A. I., Muellauer, L., Simonitsch-Klupp, I., Beham-Schmid, C., Thiele, J., Gisslinger, H., Jeryczynski, G., Albert, W., Gisslinger, B., Schalling, M., Burgstaller, S., Buxhofer-Ausch, V., Krauth, M. T., Geissler, K., Schloegl, E., Sliwa, T., Schiefer, A. I., Muellauer, L., Simonitsch-Klupp, I., Beham-Schmid, C., Thiele, J., and Gisslinger, H.

Published
2016

8. IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION

Author

Schalling, M., Gisslinger, B., Jeryczynski, G., Berg, T., Harutyunyan, A., Milosevic, J., Bagienski, K., Them, N., Schischlik, F., Buxhofer-Ausch, V., Nirnberger, G., Schiefer, A. -I., Muellauer, L., Kralovics, R., Thiele, J., Gisslinger, H., Schalling, M., Gisslinger, B., Jeryczynski, G., Berg, T., Harutyunyan, A., Milosevic, J., Bagienski, K., Them, N., Schischlik, F., Buxhofer-Ausch, V., Nirnberger, G., Schiefer, A. -I., Muellauer, L., Kralovics, R., Thiele, J., and Gisslinger, H.

Published
2015

10. High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies

Author

Pudja, A., Milosević, J. D., Klampfl, T., Harutyunyan, A., Berg, T., Bagienski, K., Chen, D., Gisslinger, B., Rumi, E., Malcovati, L., Pietra, Daniela, Elena, C., Della Porta, M. G., Pieri, Lisa, Guglielmelli, Paola, Doubek, M., Dvorakova, D., Suvajdžić, Nada, Tomin, D., Tošić, Nataša, Racil, Z., Steurer, M., Pavlović, Sonja, Vannucchi, A. M., Cazzola, M., Gisslinger, H., Kralovics, R., Pudja, A., Milosević, J. D., Klampfl, T., Harutyunyan, A., Berg, T., Bagienski, K., Chen, D., Gisslinger, B., Rumi, E., Malcovati, L., Pietra, Daniela, Elena, C., Della Porta, M. G., Pieri, Lisa, Guglielmelli, Paola, Doubek, M., Dvorakova, D., Suvajdžić, Nada, Tomin, D., Tošić, Nataša, Racil, Z., Steurer, M., Pavlović, Sonja, Vannucchi, A. M., Cazzola, M., Gisslinger, H., and Kralovics, R.

Published
2015

12. IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION

Author

Schalling, M., Gisslinger, B., Jeryczynski, G., Berg, T., Harutyunyan, A., Milosevic, J., Bagienski, K., Them, N., Schischlik, F., Buxhofer-Ausch, V., Nirnberger, G., Schiefer, A. -I., Muellauer, L., Kralovics, R., Thiele, J., Gisslinger, H., Schalling, M., Gisslinger, B., Jeryczynski, G., Berg, T., Harutyunyan, A., Milosevic, J., Bagienski, K., Them, N., Schischlik, F., Buxhofer-Ausch, V., Nirnberger, G., Schiefer, A. -I., Muellauer, L., Kralovics, R., Thiele, J., and Gisslinger, H.

Published
2015

13. Prognostic significance of genetic aberrations in secondary acute myeloid leukemia

Author

Milosević, J., Puda, Ana, Berg, T., Klampfl, T., Harutyunyan, A., Hofbauer, M., Stukalov, A., Gisslinger, H., Gisslinger, B., Burjanivova, T., Rumi, E., Pietra, Daniela, Malcovati, L., Elena, C., Cazzola, M., Vannucchi, A., Doubek, M., Penka, M., Racil, Z., Dvorakova, D., Wieser, R., Koller, E., Steurer, M., Tošić, Nataša, Pavlović, Sonja, Kralovics, R., Milosević, J., Puda, Ana, Berg, T., Klampfl, T., Harutyunyan, A., Hofbauer, M., Stukalov, A., Gisslinger, H., Gisslinger, B., Burjanivova, T., Rumi, E., Pietra, Daniela, Malcovati, L., Elena, C., Cazzola, M., Vannucchi, A., Doubek, M., Penka, M., Racil, Z., Dvorakova, D., Wieser, R., Koller, E., Steurer, M., Tošić, Nataša, Pavlović, Sonja, and Kralovics, R.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results